Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

▤ Summary

Biomea Fusion announced a research collaboration with the University of Leicester to test icovamenib with semaglutide in obesity. The study will run inside the OPAL adaptive platform trial and will compare the combination against low-dose semaglutide alone in overweight and obese adults without type 2 diabetes. Enrollment is expected to begin in the third quarter, with the primary endpoint measured at week 24. Biomea also plans to present preclinical data at the ADA Scientific Sessions to support the combination’s potential effects on weight loss, muscle, bone, and metabolic health.

▦ Linked Companies